Welcome
to Nordic Pharma

Through a combination of innovation, collaboration and quality,
Nordic Pharma strives to address specific unmet medical needs.

Accueil

About The Group

Nordic Pharma is a fully integrated international Pharma company with a history of internal product development and acquisitions.

Nordic Pharma holds a leading position in Women’s Health, a fast-growing Rheumatology franchise with global footprints and an increasing presence in Critical Care.

We bring over 25 years of expertise since our creation in 1995.

News

Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer
- by admin

Nordic Pharma has announced that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a…

Company news

Nordic Pharma has announced that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion Teysuno: Pending EC decision | European Medicines Agency (europa.eu)] recommending the use of Teysuno (tegafur/gimeracil/oteracil) for the treatment of patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to specific toxicities: hand-foot syndrome and cardiotoxicity. The CHMP supports including patients who developed these toxicities in the adjuvant setting in addition to metastatic patients.

Teysuno® is an oral fluoropyrimidine with similar efficacy, but improved safety profile compared with other fluoropyrimidines.

Based on this positive opinion Teysuno will be indicated in adults:

  • for the treatment of advanced gastric cancer when given in combination with cisplatin (current indication).
  • as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting (pending European Committee decision).
  New fluoropyrimidine for patients with metastatic colorectal cancer nordic_pharma_thumbnail_green_colon

In metastatic colorectal cancer the typical first-line chemotherapy contains of a fluoropyrimidine used in various combinations.

Jean-Michel Quinot, CEO of Nordic Pharma stated: ”This is important news for patients with metastatic colorectal cancer. Teysuno offers those patients suffering from toxicities that can cause discontinuation of therapy an alternative fluoropyrimidine therapy which allows them to continue systemic treatment that is known to significantly prolong survival. By being able to meet this medical need, we hope to contribute to improving the lives of these patients. We want to particularly thank medical oncologists and patients in different European countries who contributed to collecting crucial clinical data for this new indication.”

Iris van Lakerveld, Global Oncology Lead added: “Fluoropyrimidines are, and will continue to be, the cornerstone of chemotherapy treatment in metastatic colorectal cancer. A significant group of patients can now be offered an alternative, in the event that chemotherapy needs to be delayed, the dose reduced or fully stopped because of hand-foot syndrome or cardiotoxicity. Side effects with chemotherapy are inevitable. With Teysuno, physicians and patients will have an additional therapy when needed, allowing optimal benefit of fluoropyrimidine treatment.

Nordic Pharma has licenced Teysuno® from Taiho Pharmaceutical Co., Ltd. in Japan. In Japan, the product is known as TS-1 and is approved for various solid tumours, including gastric and colorectal cancer. Since 2011 Teysuno has been on the European market in 17 countries. In total, the product is marketed in over 30 countries worldwide.

This positive CHMP opinion is a first step in providing patients with metastatic colorectal cancer access to Teysuno. EMA’s opinion needs to be adopted by the European Commission, and subsequently country-specific reimbursement applications will be done at the level of each Member State to ensure this access.

  About Nordic Pharma

Nordic Pharma is a medium-sized, fully integrated international pharma company.

Nordic Pharma’s focus is on the development and commercialization of specialty products, which include niche hospital and orphan products, to address unmet medical needs. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: rheumatology, women’s health and critical care (anaesthesia, haematology and oncology).

Find out more on www.nordicpharma.com. Contact: oncology@nordicpharma.com

TEY-2022-01-002

Nordic Pharma present at CPhI !
- by admin

Nordic Pharma will be attending CPhI Worldwide in Milan, Italy from November 9th-11th 2021. We are actively looking for late stage partnering…

Company news
Nordic Pharma will be attending CPhI Worldwide in Milan, Italy from November 9th-11th 2021. We are actively looking for late stage partnering opportunities ideally within our core therapeutic areas of Women’s Health, Rheumatology and Critical Care. If you would like to get in touch and possibly meet us there, please contact busdev@nordicpharma.com   Nordic-Pharma-present-at-CPhI
Nordixate® Methotrexate Pre-filled Syringe approved in Colombia
- by admin

Nordic Pharma AAP is pleased to announce that the Nordixate® Methotrexate Pre-filled Syringe has been issued market authorization by Instituto…

Product launch
Nordic Pharma AAP is pleased to announce that the Nordixate® Methotrexate Pre-filled Syringe has been issued market authorization by Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or INVIMA, the Colombian National Food and Drug Surveillance Institute. With our local partner, Vitalis Laboratorio, we are working towards a launch early next year. Thank you to everyone who has been involved in achieving this approval. nordic-pharma-vitalis-expertos-en-inyectables
New Headquarters Offices
- by admin

Both of Nordic Pharma HQs, located in France and in the Netherlands, have recently moved. Nordic Pharma HQ NL has…

Company news

Both of Nordic Pharma HQs, located in France and in the Netherlands, have recently moved.

Nordic Pharma HQ NL has relocated to a new office in the Schiphol area as of June 1st, 2021. You will find our new address and phone number below:​​​​​​​

Nordic Pharma B.V. Siriusdreef 41 2132 WT Hoofddorp The Netherlands Phone number: 085 – 48 35 871

Nordic-Pharma-New Headquarters Offices

Nordic Pharma B.V., our Dutch affiliate, is also located here. 

 

Our second HQ in Paris, France, also relocated on March 1st, 2021 to the following address: 

Nordic Pharma 216 Boulevard Saint Germain 75007 Paris, France Phone number: +33 (0)1 70 37 28 02

Nordic-Pharma-New Headquarters-Offices-Paris

Portfolio of therapeutic areas

Nordic Pharma aims at developing products that address specific unmet medical needs of healthcare professionals and patients. Today, we have a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Women’s Health, Rheumatology, Critical Care, Others.

nordic-pharma-home-our-organization

Our organization

Today, Nordic Pharma is:

  • 275
    Employees
    worldwide
  • 20
    Different
    countries
  • 03
    Continents – and
    counting

We are a medium-size pharmaceutical company with an entrepreneurial spirit. As such, we promote change and encourage the development of new ideas. We create opportunities for personal and professional development.

Our Presence

Nordic Pharma has affiliates in most European countries and has established a global footprint with key strategic partnerships to promote and distribute our products worldwide.

Our headquarters (2)
Our affiliates (12)
Our commercial partners

Nordic Pharma

Nordic Group BV
216 Boulevard Saint Germain
75007 Paris
France
Tel: +33 (0)1 70 37 28 02

Nordic Pharma

Nordic Group BV
Siriusdreef 41
2132 WT Hoofddorp
The Netherlands
Tel: +31 (0)85 48 35 871

Nordic Pharma Netherlands

Nordic Pharma B.V.
Siriusdreef 41
2132 WT Hoofddorp
The Netherlands
Tel: +31 (0)85 48 35 871
www.nordicpharma.nl

Nordic Pharma France

Nordic Pharma SAS
251 Boulevard Pereire
75017 Paris
France
Tel: +33 (0) 1 70 37 28 00
www.nordicpharma.fr

Nordic Pharma Americas, Asia, Pacific

Nordic Pharma Inc.
www.nordicpharma.ca

Nordic Pharma Central Eastern Europe

7, Mircea Eliade Blvd
Bucharest
Romania
Tel: +40 31 620 1204

Nordic Pharma Italy

Nordic Pharma S.r.l
Strada Anulare Torre 10
20090 San Felice – Segrate (MI)
Italy
Tel: +39 02 7532629
www.nordicpharma.it

Nordic Pharma Spain

Nordic Pharma SAU
Adolfo Pérez Esquivel, 3. 2°.
Of. 17. Edificio Las Américas
III. 28232 Parque Empresarial
Las Rozas, Madrid, Spain
Tel: +34 916 404 041
www.nordicpharma.es

Nordic Pharma Switzerland

Nordic Pharma GmBH
Binzmühlestrasse 80, 8050
Zürich
Switzerland
Tel: +41 43 444 92 91
www.nordicpharma.ch

Nordic Pharma Ireland

Nordic Pharma Ltd
Allphar Services Ltd, 4045
Kingswood Road, Citywest
Business Park, Co. Dublin
Ireland

Nordic Pharma UK

Nordic Pharma Ltd
Unit 3 Commerce Park,
Brunel Road, Theale,
Berkshire, RG7 4AB
United Kingdom
Tel: +44 118 207 9160
www.nordicpharma.co.uk

Nordic Pharma Germany + Austria

Nordic Pharma GmBH
Fraunhoferstraße 4 D-85737
Ismaning
Germany
Tel: +49 (0) 89 88 96 90 68 -0
www.nordicpharma.de

Nordic Pharma Scandinavia

Nordic Drugs AB
Box 300 35, 200 61
Limhamn
Sweden
Tel: +46 40 36 66 00
www.nordicdrugs.com

Nordic Pharma Belgium + Luxembourg

Nordic Pharma N.V.
Garden Square, Laarstraat 16
2610 Wilrijk
Belgium
Tel: +32 (0)3 820 52 24
https://www.nordicpharma.be/

Click on the location for more details.
map-head-default-v5
map-france3
the-Netherlands-map-v5
map
the-Netherlands
France-map
Nordic-Canada
Romania-map-v6
Italy-map
Spain-portugal-map-v2
Switzerland-map
Nordic_Pharma_Ireland-V3-1
Nordic_Pharma_UK-V3-1
Nordic_Pharma_Germany
Nordic_Drugs-v5
commercial-partners-map-6